In the methodology section of the abstract the term "pathological" was used incorrectly and should be "biochemical" instead. The corrected sentence reads: "The remaining cases received additional doses of TCBZ with complete clinical, biochemical, and radiological resolution."

There is a typographical error in the footnote of [Table 5](#pntd.0008443.t001){ref-type="table"}. In the updated [Table 5](#pntd.0008443.t001){ref-type="table"}, the reference range for platelet count in the footnote has been updated to 150,000--450,000/µL.
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###### Laboratory data of the studied patients who received first line triclabendazole.

![](pntd.0008443.t001){#pntd.0008443.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------
                                       Non- responders to TCBZ\   Responders to TCBZ\   *P* value
                                       (n = 30)                   (n = 37)              
  ------------------------------------ -------------------------- --------------------- -----------------------------------------------
  **Hb level** (g/dl):                 11.80 ± 1.13               11.81 ± 0.90          0.930

  **WBCs** (cells/µL):                 17.46 ± 12.25              10.27 ± 3.92          0.008[^\*^](#t001fn003){ref-type="table-fn"}

  **Eosinophils % before treatment**   26.72 ± 13.21\             30.47 ± 15.18\        0.081
                                       *Range = 14--40%*          *Range = 7--70%*      

  **Eosinophils % after treatment**    20.00 ± 11.28\             3.6 ± 1.7\            0.0001[^\*^](#t001fn003){ref-type="table-fn"}
                                       *Range = 3--59%*           *Range = 1--15%*      

  **PLT** (cells/µL)                   311.60 ± 85.07             308.11 ± 75.79        0.796

  **Total bilirubin** (mg/dl)          1.04 ± 0.15                1.06 ± 0.17           0.613

  **ALT** (IU/L)                       61.43 ± 43.44              39.62 ± 18.52         0.026[^\*^](#t001fn003){ref-type="table-fn"}

  **AST** (IU/L)                       53.83 ± 36.05              35.78 ± 15.84         0.047[^\*^](#t001fn003){ref-type="table-fn"}

  **Positive stool analysis**          2 (6.7%)                   5 (13.5%)             0.447

  **Serology titer**                   885.33 ± 391.32            977.30 ± 384.19       0.338
  -------------------------------------------------------------------------------------------------------------------------------------

**Hb,** hemoglobin; **WBCs,** white blood cells; **PLT,** platelets count; **ALT,** alanine aminotransferase; **AST**, aspartate aminotransferase.

Reference ranges: Hb (male) = 14--17 g/dL; Hb (female) = 12--16 g/dL; WBCs = 4000--10,000/μL; eosinophils = 0--5%; PLT count = 150,000--450,000/μL; total bilirubin = 0.3--1.2 mg/dL; ALT = 0--35 IU/L; AST = 0--35 IU/L. Serology titer ≥ 1/320 is considered positive.

\* Significant *p*-value by Fisher exact test.
